Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

Standard of care

Standard of care

Resectable head and neck adenoid cystic carcinoma is principally managed with surgery and postoperative radiotherapy. Recurrent or metastatic disease has no universally preferred systemic regimen and no identified ACC specific FDA approved systemic therapy as of November 7, 2026. VEGFR tyrosine kinase inhibitors have activity but are off label. Named MYB directed and antibody drug conjugate programs in the review remain investigational.

NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.

No drugs selected. The grid shows every stated option.

How to read a tile

  • Filled tile. Approved for that lane.
  • Outlined tile. Guideline or off label. Local, Exception, and Not established use the same outline with those words.
  • Dashed tile. Investigational, with the phase and any stated FDA date. Pending review is not approval.

An empty cell reads “No standard.” The words on the tile carry the status. Border style repeats it.

SubgroupSurgeryRadiotherapyObservationSystemic therapy
Resectable head and neckASCO recommends surgery and postoperative radiotherapy, including early stage disease.

No standard

No standard

UnresectableDefinitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.

No standard

No standard

No standard

Isolated local recurrenceThe review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.

No standard

No standard

Recurrent or metastatic, asymptomatic slow growthMonitored observation can be appropriate for asymptomatic, slowly growing lung only disease.

No standard

No standard

No standard

Recurrent or metastatic, symptoms or growthThe review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.

No standard

No standard

No standard

Labeled biomarker presentA tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.

No standard

No standard

No standard

Surgery

Resectable head and neck

ASCO recommends surgery and postoperative radiotherapy, including early stage disease.

Unresectable

Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.

No standard

Isolated local recurrence

The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.

Recurrent or metastatic, asymptomatic slow growth

Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.

No standard

Recurrent or metastatic, symptoms or growth

The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.

No standard

Labeled biomarker present

A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.

No standard

Radiotherapy

Unresectable

Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.

Isolated local recurrence

The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.

Recurrent or metastatic, asymptomatic slow growth

Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.

No standard

Recurrent or metastatic, symptoms or growth

The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.

No standard

Labeled biomarker present

A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.

No standard

Observation

Resectable head and neck

ASCO recommends surgery and postoperative radiotherapy, including early stage disease.

No standard

Unresectable

Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.

No standard

Isolated local recurrence

The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.

No standard

Recurrent or metastatic, asymptomatic slow growth

Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.

Recurrent or metastatic, symptoms or growth

The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.

No standard

Labeled biomarker present

A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.

No standard

Systemic therapy

Resectable head and neck

ASCO recommends surgery and postoperative radiotherapy, including early stage disease.

No standard

Unresectable

Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.

No standard

Isolated local recurrence

The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.

No standard

Recurrent or metastatic, asymptomatic slow growth

Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.

No standard

Recurrent or metastatic, symptoms or growth

The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.

Labeled biomarker present

A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.

Sources

  • A1ASCO management of salivary gland malignancyGeiger et al., JCO 2021.
  • A2ESMO EURACAN salivary gland cancer guideline2022 European guideline.
  • A3AJCC version 9 salivary gland staging changesHuang et al., Annals of Surgical Oncology 2026. Implementation January 1, 2026.
  • A4Onkopedia salivary gland carcinomasJune 2026 international specialist guidance.
  • A5Postoperative radiotherapy in resected head and neck ACCChoi et al., Radiation Oncology 2022. Retrospective cohort.
  • A6Phase II lenvatinib in recurrent or metastatic ACCTchekmedyian et al., JCO 2019. Single arm.
  • A7Randomized axitinib versus observation in recurrent or metastatic ACCKang et al., Clinical Cancer Research 2021.
  • A8Phase II axitinib plus avelumab in recurrent or metastatic ACCFerrarotto et al., JCO 2023. Single arm.
  • A9Molecular subtypes and outcomes with axitinib plus avelumabHoff et al., Clinical Cancer Research 2026. Reports NCCN category 2B inclusion, not independently checked against a current full NCCN.
  • A10CAP chemotherapy in recurrent or metastatic ACCHa et al., Chinese Clinical Oncology 2020. 14 patient retrospective series.
  • A11Phase II rivoceranib in recurrent or metastatic ACCHanna et al., Clinical Cancer Research 2023. Single arm. Investigational in ACC.
  • A12Randomized pembrolizumab with or without radiation in ACCMahmood et al., IJROBP 2021. 20 patients.
  • A13Genomic evolution and targets in ACCHo et al., JCI 2019.
  • A14Survival outcomes of pulmonary metastasis directed therapy in ACCHoff et al., Cancer 2025. Retrospective analysis.
  • A15NCI salivary gland cancer treatment PDQU.S. evidence summary.
  • A16Surveillance after treatment of head and neck ACC2025 institutional outcomes and a proposed protocol. Not a randomized surveillance trial.
  • A17REM-422 clinical trialNCT06118086. Investigational MYB mRNA degrader.
  • A18RGT-61159 clinical trialPhase I MYB directed program. Registry updated September 2026.
  • A19UCSF ACC clinical trial listingsIncludes emiltatug ledadotin and SOLAR. Eligibility must be rechecked.
  • A20KROG 22-14 breast adenoid cystic carcinoma cohort2025 multicenter retrospective study.
  • A21Lacrimal gland ACC outcomes cohort2026 retrospective study.
  • A22Tracheal ACC multicenter treatment outcomesCancer Medicine 2025.
  • A23LENVIMA U.S. prescribing informationLenvatinib safety. ACC use is off label.
  • A24BAVENCIO U.S. prescribing informationAvelumab safety. ACC use is off label.
  • X1NCI tissue agnostic cancer therapies PDQBiomarker specific eligibility and label restrictions apply.
  • X2FDA accelerated approval of trastuzumab deruxtecan for HER2 positive solid tumorsApril 5, 2024. HER2 IHC 3+, prior treatment, and no satisfactory alternatives.
  • ASCO-6009REM-422, ASCO 2026 abstract 6009Abstract already quoted in the ACC seed. Preliminary.
  • NCT03691207ACCURACY, ClinicalTrials.govRegistry results already quoted in the ACC seed.
  • NCT02098538Regorafenib in ACC, ClinicalTrials.govRegistry results already quoted in the ACC seed.

All drugs